A groundbreaking treatment, retatrutide, is generating considerable anticipation within the Oz weight loss community. Developed by Eli Lilly , this combination GIP and GLP-1 receiver appears to offer more substantial results than present therapies. Early clinical studies have shown exceptional decreases in overall mass, indicating the potential for